ReviewExperimental hematology & oncology2026
Prospects and advances of PROTAC in the treatment of hematologic malignancies.
Review in Experimental hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Over the past years, target protein degradation (TPD) has emerged as a hot topic in treating hematologic malignancies out of its strong ability to eliminate pathological proteins precisely. And as a flagship, Proteolysis-Targeting Chimeras (PROTACs) hijack the ubiquitin- proteasome system to catalytically degrade protein of interest (POI). Compared to small-molecule inhibitors (SMIs) and Chimeric antigen receptor T-cell (CAR-T) therapies, PROTACs exhibit distinct advantages in mechanism of action, toxicity profile, specificity, diversity of targets, and ability to overcome drug resistance. In this review, we comprehensively summarize PROTAC drugs that have entered clinical trials, with particular focus on eight candidates being developed for hematologic malignancies. We also classified 56 protein targets whose PROTACs are in pre-clinical stage into seven groups based on their functions, including "epigenetic regulators", "kinases", "RNA regulators", "transcriptional regulators", "protein regulators", and so on. In summary, this review synthesizes the current landscape of PROTAC therapeutics in hematologic malignancies and provides perspectives on future development directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.